L-carnitine reduces CFS fatigueAssociation between fatigue, peripheral serotonin, and L-carnitine in hypothyroidism and in chronic fatigue syndrome.
We aimed to explore how L-carnitine supplementation affects individuals suffering from chronic fatigue syndrome (CFS) by analyzing their serotonin levels and fatigue symptoms. Our study focused on a group of 12 individuals with CFS and compared their serotonin and fatigue levels before and after 7 weeks of L-carnitine treatment.
Remarkably, we observed that after the supplementation, serotonin levels in those with CFS increased drastically—by eight times! Alongside this boost in serotonin, participants reported a significant two-fold reduction in fatigue symptoms, which was noteworthy given the persistent fatigue commonly experienced in CFS.
These findings also revealed a strong negative correlation between serotonin levels and fatigue, suggesting that higher serotonin is associated with lower fatigue levels. This paints a promising picture of L-carnitine as a potential treatment for managing fatigue in CFS, contributing to a better quality of life for those affected.
Read More
ALC reduces fatigue in elderlyAcetyl L-carnitine (ALC) treatment in elderly patients with fatigue.
We investigated the effects of acetyl L-carnitine (ALC) on elderly patients experiencing chronic fatigue. In our study of 96 participants aged 70 and above, we found that ALC significantly reduced both physical and mental fatigue.
After treatment, improvements were noted in functional abilities and cognitive performance, with patients experiencing less muscle pain and fewer sleep disorders. Overall, our findings indicate that ALC can be an effective option for alleviating fatigue and enhancing quality of life in older individuals.
Read More
ACCAR surpasses amantadine for fatigueComparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.
We explored the effectiveness of acetyl L-carnitine (ALCAR) in treating fatigue among patients with multiple sclerosis, comparing it to amantadine. In a robust randomized, double-blind, crossover trial involving 36 participants, ALCAR showed a significant improvement in fatigue levels on the Fatigue Severity Scale after three months compared to amantadine. However, when looking at secondary outcomes, like depression and social experiences, no significant differences were noted. Overall, ALCAR proved to be better tolerated and more effective for managing fatigue in this population.
Read More
L-carnitine reduces treatment-induced fatigueL-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C.
We evaluated how L-carnitine impacts fatigue in patients undergoing treatment for chronic hepatitis C. The study involved 50 patients split into two groups: one received just interferon-alpha, while the other received interferon alongside L-carnitine.
We discovered that those taking L-carnitine reported a significant reduction in fatigue levels, particularly noticed early on in treatment. By contrasting these observations, we suggested that L-carnitine may enhance energy levels, effectively helping alleviate treatment-induced fatigue in these patients.
Read More
L-carnitine shows mixed effectsDietary Supplementation for Fatigue Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systematic Review.
We set out to explore how l-carnitine, a common dietary supplement, affects individuals suffering from chronic fatigue syndrome (CFS). By conducting a systematic review of fourteen studies involving 809 participants, we aimed to gather reliable evidence about the effectiveness of l-carnitine in alleviating fatigue, one of the primary symptoms of this complex disorder.
Many patients turn to dietary supplements like l-carnitine to find relief from their fatigue and its accompanying symptoms. Our review found that while some studies reported a significant reduction in fatigue from interventions that included l-carnitine, we also noticed methodological challenges that limit these findings. Issues such as small sample sizes and missing data led to a high risk of bias, which makes it hard to draw clear conclusions about the supplement's effectiveness on its own.
Additionally, our review highlighted mixed results when it came to secondary outcomes, such as cognitive function and biomarkers of inflammation. Some participants did report adverse effects, like nausea and insomnia, which adds another layer of complexity in assessing the use of l-carnitine for CFS. Overall, while l-carnitine shows potential benefits for reducing fatigue, the limitations of the current studies make us cautious about confirming its isolated effectiveness.
Read More